Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.
Thanks to the work of NEI scientists and grantees, we’re constantly learning new information about the causes and treatment of vision disorders. Get the latest updates about their work — along with other news about NEI.
Researchers and clinicians at the University of Southern California Roski Eye Institute have published results of the NEI-funded “Chinese American Eye Study” in JAMA Ophthalmology.
Diabetes-related vision loss most often is blamed on blood vessel damage in and around the retina, but new research indicates that much of that vision loss may result from nerve cell injury that occurs long before any blood vessels are damaged.
A two-year clinical trial that compared three drugs for diabetic macular edema (DME) found that gains in vision were greater for participants receiving the drug Eylea (aflibercept) than for those receiving Avastin (bevacizumab).
A clinical trial funded by the National Institutes of Health has found that the drug ranibizumab (Lucentis) is highly effective in treating proliferative diabetic retinopathy.
Researchers funded in part by the National Eye Institute (NEI) have identified a protein involved in an advanced stage of diabetic retinopathy, a diabetic eye disease that threatens vision.
People with type 1 diabetes who intensively control their blood glucose (blood sugar) early in their disease, versus those who do not, are 48 percent less likely to need eye surgery, and the total number of such surgeries is 37 percent less.
In an NIH-supported clinical trial comparing three drugs for diabetic macular edema (DME), Eylea (aflibercept) provided greater visual improvement, on average, than did Avastin (bevacizumab) or Lucentis (ranibizumab) when vision was 20/50 or worse.